| Autor: |
Khantong Khiewngam, Songporn Oranratnachai, Kaettipong Kamprerasart, Patratorn Kunakorntham, Pimtip Sanvarinda, Narumol Trachu, Pongput Pimsa, Jirapath Wiwitkeyoonwong, Thanaporn Thamrongjirapat, Thitiya Dejthevaporn, Ekaphop Sirachainan, Thanyanan Reungwetwattana |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology, Vol 13 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2234-943X |
| DOI: |
10.3389/fonc.2023.1047644 |
| Popis: |
BackgroundDespite significant benefits of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with EGFR-mutated NSCLC, access remains limited in Thailand and elsewhere.MethodsRetrospective analysis of patients with locally advanced/recurrent NSCLC and known EGFR mutation (EGFRm) status treated at Ramathibodi Hospital (2012–2017). Prognostic factors for overall survival (OS), including treatment type and healthcare coverage, were analyzed using Cox regression.ResultsOf 750 patients, 56.3% were EGFRm-positive. After first-line therapy (n=646), 29.4% received no subsequent (second-line) treatment. EGFR-TKI-treated EGFRm-positive patients survived significantly longer than EGFRm-negative patients without EGFR-TKIs (median OS [mOS] 36.4 vs. 11.9 months; hazard ratio HR=0.38 [95%CI 0.32–0.46], P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
